Dragonfly Therapeutics

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts. The company employs 123 people and generates approximately $50 million in annual revenue. Dragonfly Therapeutics focuses on developing innovative therapies that leverage the body's immune system to combat diseases. Their proprietary multispecific antibody technology is at the heart of their approach, aiming to bring groundbreaking treatments to patients. The company's portfolio includes both clinical assets and a robust pipeline of preclinical candidates developed using its innovative platform. Beyond its own research and development, Dragonfly Therapeutics actively collaborates with leading pharmaceutical companies such as Merck, AbbVie, Gilead, and Bristol Myers Squibb. These partnerships expand their reach and expertise across a wide spectrum of disease areas. To learn more about Dragonfly Therapeutics and its groundbreaking work, interested parties are encouraged to contact the company via email at [email protected].